摘要
风湿病的传统治疗以激素和甲氨蝶呤为代表的改善病情药物为主,随着分子水平研究的深入,以肿瘤坏死因子α阻断剂为代表的多种靶向生物制剂进入临床。药物的选择性治疗必须依靠基因组及药物遗传学的研究,对不同患者疗效及药物毒副反应作个体化的分析,从而正确的选择药物。本文就风湿病的传统的甲氨蝶呤和TNF-α阻断剂在药物基因组学预测药物的疗效及副作用等进行综述。
Methotrexate and glucocorticoid as the representative of improving condition-based drugs used in traditional treatment of rheumatism,with study of the molecular level depth,the tumor necrosis factor α blockers as the representative of a variety of targeted biological agents come into the clinic.The selective drug treatment must rely on pharmacogenetics,analysising different patients out-comes and drug toxicity for individual to choose the right medicine.We reviewed the traditional methotrexate and TNF-α blockers in pharmacogenomics predict drug efficacy and adverse effects in rheumatism.
出处
《现代生物医学进展》
CAS
2012年第1期198-200,194,共4页
Progress in Modern Biomedicine
基金
上海市科委基础研究重点项目(08JC1406300)
